Home
|
Inbox
|
Search
|
View Abstract
New Opportunities for Monitoring Patients with Bronchiectasis
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A7808 - New Opportunities for Monitoring Patients with Bronchiectasis
Author Block: G. Ignatova, V. Antonov; Therapy, South Ural State Medical University, Chelyabinsk, Russian Federation.
Mucoactive drugs are used to control patients with bronchiectasis. A hypertonic solution of 7% NaCl is successfully used as a mucolytic drug with an indirect effect on the bronchial secretion for a sufficient amount of time. A new form is a combination of 7% NaCl and 0.1% hyaluronic acid (Gianeb). The aim of this study was to evaluate the effectiveness of the combined Gianeb drug in patients with bronchiectasis. Material and Methods: 99 patients were included in the study, age 58.96 (54.31, 63.62) years. Analyzed: the degree of dyspnea for mMRC, the frequency of infectious exacerbations of bronchiectasis and hospitalizations. Patients were divided into 2 groups: 1st group (n = 50, 36 women and 14 men) - standard therapy (antibacterial drugs with exacerbations, mucolytics) 2nd (n = 49; 37 women and 12 men) - in addition Gianeb was appointed (5 ml twice a day, for 30 days, then at the onset of symptoms of exacerbation). The follow-up period was 6 months. Results and Discussions: The groups were comparable in age and other clinical indices, there were no significant differences (p> 0.05). After 6 months of observation the degree of dyspnea significantly decreased in patients of the 2nd group from 3.76 (3.32, 4.19) to 2.18 (1.52, 2.84) points. There were no significant FEV1 dynamics. Against the background of the use of the drug Gianeb there is a more pronounced decrease in the number of exacerbations (3 times) and related hospitalizations. Conclusions: Gianeb 5 ml use the nebulizer allows more effective control of the course in patients with bronchiectasis. Inclusion of the drug in the treatment plan significantly reduces the number of exacerbations and the number of exacerbations associated with it. Application of 7% hypertonic NaCl solution with hyaluronic acid can be considered as a variant of ""non-invasive sanation bronchoscopy"".
Author Block: G. Ignatova, V. Antonov; Therapy, South Ural State Medical University, Chelyabinsk, Russian Federation.
Mucoactive drugs are used to control patients with bronchiectasis. A hypertonic solution of 7% NaCl is successfully used as a mucolytic drug with an indirect effect on the bronchial secretion for a sufficient amount of time. A new form is a combination of 7% NaCl and 0.1% hyaluronic acid (Gianeb). The aim of this study was to evaluate the effectiveness of the combined Gianeb drug in patients with bronchiectasis. Material and Methods: 99 patients were included in the study, age 58.96 (54.31, 63.62) years. Analyzed: the degree of dyspnea for mMRC, the frequency of infectious exacerbations of bronchiectasis and hospitalizations. Patients were divided into 2 groups: 1st group (n = 50, 36 women and 14 men) - standard therapy (antibacterial drugs with exacerbations, mucolytics) 2nd (n = 49; 37 women and 12 men) - in addition Gianeb was appointed (5 ml twice a day, for 30 days, then at the onset of symptoms of exacerbation). The follow-up period was 6 months. Results and Discussions: The groups were comparable in age and other clinical indices, there were no significant differences (p> 0.05). After 6 months of observation the degree of dyspnea significantly decreased in patients of the 2nd group from 3.76 (3.32, 4.19) to 2.18 (1.52, 2.84) points. There were no significant FEV1 dynamics. Against the background of the use of the drug Gianeb there is a more pronounced decrease in the number of exacerbations (3 times) and related hospitalizations. Conclusions: Gianeb 5 ml use the nebulizer allows more effective control of the course in patients with bronchiectasis. Inclusion of the drug in the treatment plan significantly reduces the number of exacerbations and the number of exacerbations associated with it. Application of 7% hypertonic NaCl solution with hyaluronic acid can be considered as a variant of ""non-invasive sanation bronchoscopy"".
|
Home
|
Inbox
|
Search
|